--- title: "CureVac (NASDAQ:CVAC) Shares Gap Up - Here's Why" description: "CureVac (NASDAQ:CVAC) shares gapped up from $3.26 to $3.37 before trading, closing at $3.35 with a volume of 42,511 shares. JMP Securities maintained a \"market outperform\" rating with a $16.00 price t" type: "news" locale: "en" url: "https://longbridge.com/en/news/237715603.md" published_at: "2025-04-27T14:44:52.000Z" --- # CureVac (NASDAQ:CVAC) Shares Gap Up - Here's Why > CureVac (NASDAQ:CVAC) shares gapped up from $3.26 to $3.37 before trading, closing at $3.35 with a volume of 42,511 shares. JMP Securities maintained a "market outperform" rating with a $16.00 price target. The company reported a quarterly EPS of ($0.15), missing estimates, but revenue was $15.44 million, exceeding expectations. CureVac focuses on mRNA-based medicines and has a market cap of $760.51 million. Institutional investors hold 17.26% of the stock, with notable increases in stakes from several hedge funds. Shares of CureVac (NASDAQ:CVAC - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $3.26, but opened at $3.37. CureVac shares last traded at $3.35, with a volume of 42,511 shares trading hands. ## Wall Street Analysts Forecast Growth - 2 Small-Cap Stocks Set to Shine in a Bull Market Separately, JMP Securities reiterated a "market outperform" rating and set a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th. **View Our Latest Report on CVAC** ## CureVac Stock Performance - 3 Stocks to Buy For the COVID Resurgence The company has a market capitalization of $760.51 million, a P/E ratio of 6.15 and a beta of 2.48. The stock's fifty day moving average price is $3.04 and its 200-day moving average price is $3.17. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The business had revenue of $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. As a group, research analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year. ## Hedge Funds Weigh In On CureVac Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC lifted its stake in shares of CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after buying an additional 55,867 shares during the last quarter. Barclays PLC acquired a new stake in CureVac during the third quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of CureVac by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock worth $162,000 after acquiring an additional 4,425 shares during the period. Signaturefd LLC grew its position in shares of CureVac by 29.2% in the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company's stock valued at $123,000 after purchasing an additional 8,170 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of CureVac by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after purchasing an additional 22,491 shares during the period. 17.26% of the stock is owned by institutional investors. ## CureVac Company Profile (Get Free Report) CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. ## Read More - Five stocks we like better than CureVac - What Investors Need to Know About Upcoming IPOs - Short Sellers Gave Up on These 3 Names Recently - Insider Trades May Not Tell You What You Think - 3 Boring Stocks Outperforming the Market This Year - What Are Dividend Contenders? Investing in Dividend Contenders - If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in CureVac Right Now? Before you consider CureVac, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list. While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CVAC.US - CureVac BV](https://longbridge.com/en/quote/CVAC.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Biotalys 計劃將戰略重點放在核心產品上，同時降低成本並開發生物殺菌劑 | Biotalys NV 正在戰略性地重新聚焦其運營，以集中於關鍵項目並簡化其運營結構。該公司計劃裁減 30 名員工，並暫停早期開發活動，以降低運營成本。重點將放在推進並獲得其主要生物殺真菌劑項目 EVOCA NG 和 BioFun-6 的監 | [Link](https://longbridge.com/en/news/275304861.md) | | Option NV 進行股票整合 | Option NV 進行了股票合併。因此，股票總數發生了變化。免責聲明：本新聞簡報由公共技術公司（PUBT）使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。 | [Link](https://longbridge.com/en/news/275083028.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.